1	Se	se	P00CN000	-	-	0-2	530(3)_ANS_clinical_caseMIR	SENT1	-	-
2	trata	tratar	VMIP3S0	-	-	3-8	530(3)_ANS_clinical_caseMIR	SENT1	-	-
3	de	de	SPS00	C0332285	atributo	9-11	530(3)_ANS_clinical_caseMIR	SENT1	-	-
4	una	una		C0205447_1	calificador_1	12-15	530(3)_ANS_clinical_caseMIR	SENT1	-	-
5	artritis	artritis	NCFN000	C0003864	hallazgo#trastorno	16-24	530(3)_ANS_clinical_caseMIR	SENT1	B-Grp_Enfermedad	-
6	gotosa	gotoso	NCFS000	-	-	25-31	530(3)_ANS_clinical_caseMIR	SENT1	B-Calificador	-
7	aguda	agudo	AQ0FS0	C0205178	calificador	32-37	530(3)_ANS_clinical_caseMIR	SENT1	B-Calificador	-
8	de	de	SPS00	C0332285	atributo	38-40	530(3)_ANS_clinical_caseMIR	SENT1	-	-
9	la	el	DA0FS0	-	-	41-43	530(3)_ANS_clinical_caseMIR	SENT1	-	-
10	cadera	cadera	NCFS000	C0019552	estructura_corporal	44-50	530(3)_ANS_clinical_caseMIR	SENT1	B-Estructura_Corporal	-
11	.	.	Fp	-	-	50-51	530(3)_ANS_clinical_caseMIR	SENT1	-	-

1	Debe	deber	VMIP3S0	-	-	52-56	530(3)_ANS_clinical_caseMIR	SENT2	-	-
2	asociar	asociar	VMN0000	-	-	57-64	530(3)_ANS_clinical_caseMIR	SENT2	-	-
3	se	se	PP3CN000	-	-	64-66	530(3)_ANS_clinical_caseMIR	SENT2	-	-
4	alopurinol	alopurinol	NC00SC0	C0002144	sustancia	67-77	530(3)_ANS_clinical_caseMIR	SENT2	B-Grp_Medicamento	-
5	y	y	CC	C1706368	calificador	78-79	530(3)_ANS_clinical_caseMIR	SENT2	-	-
6	aumentar	aumentar	VMN0000	-	-	80-88	530(3)_ANS_clinical_caseMIR	SENT2	-	-
7	la	el	DA0FS0	-	-	89-91	530(3)_ANS_clinical_caseMIR	SENT2	-	-
8	analgesia	analgesia	NCFS000	C0344307	hallazgo	92-101	530(3)_ANS_clinical_caseMIR	SENT2	B-Grp_Medicamento	-
9	si	si	CS	-	-	102-104	530(3)_ANS_clinical_caseMIR	SENT2	-	-
10	precisa	precisar	VMIP3S0	-	-	105-112	530(3)_ANS_clinical_caseMIR	SENT2	-	-
11	,	,	Fc	-	-	112-113	530(3)_ANS_clinical_caseMIR	SENT2	-	-
12	recurriendo	recurrir	VMG0000	-	-	114-125	530(3)_ANS_clinical_caseMIR	SENT2	-	-
13	a	a	SPS00	-	-	126-127	530(3)_ANS_clinical_caseMIR	SENT2	-	-
14	opioides	opioides	NC00AO0	-	-	128-136	530(3)_ANS_clinical_caseMIR	SENT2	B-Grp_Medicamento	-
15	mayores	mayor	AQ0CP0	C0205164#C1704243#C0549177	calificador	137-144	530(3)_ANS_clinical_caseMIR	SENT2	-	-
16	.	.	Fp	-	-	145-146	530(3)_ANS_clinical_caseMIR	SENT2	-	-

